Daratumumab 2023 Reimbursement Ratio

Daratumumab is a revolutionary drug used to treat multiple myeloma (Multiple Myeloma), a malignant bone marrow tumor. The drug belongs to a class of monoclonal antibodies that target the CD38 receptor in the immune system, which is overexpressed on the surface of abnormal plasma cells in patients with multiple myeloma. By binding to the CD38 receptor, daratumumab triggers the immune system's attack and destruction of cancer cells.

Daratumumab has been launched in China and has been included in medical insurance. Patients can purchase it domestically. The price is about more than 5,000. Medical insurance reimbursement must meet the reimbursement conditions. For specific prices and medical insurance policies, please consult the local hospital pharmacy or medical insurance bureau. Currently, there is only the original drug of daratumumab in foreign countries. The cheaper one is the Turkish original drug, which costs around 5,000. The ingredients and efficacy are consistent with the domestic original drug.

DaThe introduction of raltuzumab marks a major breakthrough in the treatment of multiple myeloma. In the past, multiple myeloma has been a difficult-to-treat form of leukemia, with limited treatment options and poor patient survival rates. However, the emergence of daratumumab has changed this situation, providing a more effective treatment that enables many patients to achieve long-term remission and survival.

The uniqueness of this drug lies in its precise targeting, which minimizes damage to normal cells, thereby reducing side effects. Although some discomfort, such as infection, anemia, fatigue, etc., may occur, these are usually manageable.

In addition to multiple myeloma, daratumumab has also shown potential in the treatment of other leukemias and lymphomas, providing new directions for broader tumor research and treatment.